Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section

November 12, 2026 updated by: Nevine Mostafa Soliman, Menoufia University

Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section: A Prospective Randomized Study

compare Perfusion Index with Internal Jugular Vein Collapsibility Index (IJVCI) as a predictor for post-spinal hypotension in parturient undergoing elective caesarean section.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

  • Pre-anesthetic evaluation (History-Investigation - Examination) the day before surgery.
  • NPO: 8 hours for solids, 2 hours for clear fluids.
  • Pre-medication: Ranitidine 50 mg IV + Metoclopramide 10 mg IV, 30 minutes before anesthesia.
  • 18-G IV cannula in the non-dominant forearm.
  • Standard monitoring in the operating room: pulse oximetry (SpO2), NIBP, and ECG.
  • Baseline measurements (HR, SBP, DBP, MAP, SpO2, PI, CI, IJVCI) recorded in the supine position with 15 degree left lateral tilt.
  • All indicators will be measured in a single group before spinal anesthesia and comparisons will be made for the most sensitive maneuver in prediction of post spinal hypotension.
  • Cardiac Index (CI) will be measured using cardiometry before spinal anesthesia.
  • Perfusion Index (PI) is measured (Three consecutive readings are recorded at 1-minute intervals, will be repeated with another reading after delivery of baby).• The cut-off applied is: -
  • 3.5 or less (low risk for hypotension)
  • Greater than 3.5 (high risk for hypotension)
  • Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. (The patient is placed supine with 15 degree left lateral tilt, The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing).
  • Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% .
  • The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle.
  • Images will be saved for offline analysis.
  • The cut-off applied is:

IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after spinal anesthesia in CS.

  • Spinal anesthesia with intrathecal drug regimen 10-12 mg of 0.5% hyperbaric bupivacaine plus 25 micrograms (mic) Fentanyl].
  • Co-loading with Ringer's lactate at 10ml/Kg will be administrated, along with spinal anesthesia placement .Data Collection

Baseline:

  1. Patient demographic data (age, ASA physical status, comorbidities, current medications, and BMI).
  2. Hemodynamics (Heart rate- Mean Arterial Blood Pressure - Systolic Blood Pressure -Oxygen Saturation) baseline reading before induction of spinal anesthesia.
  3. Preoperative IJVCI measurement by ultrasound imaging in supine position.
  4. Preoperative Perfusion Index reading.
  5. Preoperative Cardiac index reading.

Intraoperative:

  1. Hemodynamic parameters (SBP, DBP, MAP, HR, SpO2) are recorded: -

    • Every 1 minute for the first 10 minutes,
    • Every 3 minutes until delivery,
    • Every 5 minutes thereafter until end of surgery.
  2. Total phenylephrine dose in microgram & Total Ephedrine dose (mg) [if persistent hypotension].

  3. Total IV fluid volume (mL)

  4. Total Blood loss (mL)

  5. Total Urine output (mL)

  6. Time from spinal block to delivery (min)

  7. Total time of surgery.

  8. All adverse events (nausea, vomiting, hypotension, bradycardia, oxygen desaturation) are recorded throughout.

Definition of Outcomes All outcome definitions are pre-specified and uniformly applied across all patients: -

  • Post-spinal hypotension: A fall in systolic blood pressure (SBP) below 90 mmHg.
  • Episodes are recorded from the time of spinal injection until delivery of the baby.
  • Bradycardia: Heart rate below 50 beats per minute requiring pharmacological treatment with atropine 0.01 mg/kg IV.

Treatment of PSH

  • First-line: 200 mL Ringer's lactate rapid IV infusion.
  • If SBP remains below 90 mmHg phenylephrine 25-100 microgram if persistent hypotension gives Ephedrine 5-15 mg IV bolus.
  • Bradycardia (HR < 50 bpm): Atropine 0.01 mg/kg IV.
  • All vasopressor doses and additional fluid volumes administered are recorded.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Alexandria, Egypt
        • Recruiting
        • Menoufia University,Faculty of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Adults undergoing Elective Cesarean Section at Menoufia University Hospitals

Description

Inclusion Criteria:

  • Full-term pregnant women undergoing elective cesarean section under spinal anesthesia (gestational age >= 37 weeks), singleton pregnancy.

    • Age: 18-40 years.
    • ASA I, II.
    • BMI: 18.5-35 kg/m2.

Exclusion Criteria:

  • • Patient refusal or inability to provide informed consent.

    • Emergency cesarean section.
    • Known contraindications to spinal anesthesia (coagulopathy, local infection, elevated ICP).
    • Baseline hypotension (SBP < 100 mmHg) prior to spinal anesthesia.
    • Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia).
    • Placenta previa or antepartum hemorrhage.
    • Multiple pregnancy or known fetal abnormality.
    • BMI > 35 kg/m2.
    • Pre-existing cardiovascular, cerebrovascular, or significant pulmonary disease.
    • Gestational diabetes or uncontrolled systemic disease.
    • Hemoglobin < 8 g/dL or known haemoglobinopathy.
    • Peripheral vascular disease affects pulse oximetry signal quality.
    • More than two attempts at lumbar puncture or failed.
    • Inadequate spinal block.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Perfusion Index (PI) group measured by pulse oximeter
  • Perfusion Index (PI) is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent).
  • The probe is placed on the right index finger in the supine position before induction of spinal anesthesia block.
  • Three consecutive readings are recorded at 1-minute intervals.
  • These steps will be repeated with another reading after delivery of baby.
  • Then the mean value is used as the baseline PI.
  • The cut-off applied is: -
  • 3.5 or less (low risk for hypotension)
  • Greater than 3.5 (high risk for hypotension)

is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent).

  • The probe is placed on the right index finger in the supine position before induction of spinal anesthesia block.
  • Three consecutive readings are recorded at 1-minute intervals.
  • These steps will be repeated with another reading after delivery of baby.
  • Then the mean value is used as the baseline PI.
  • The cut-off applied is: -
  • 3.5 or less (low risk for hypotension)
  • Greater than 3.5 (high risk for hypotension)
Internal Jugular Vein Collapsibility Index group will be measured by ultrasonography
  • Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe.
  • The patient is placed supine with 15 degree left lateral tilt.
  • The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing.
  • Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% [20].
  • The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle .
  • Images will be saved for offline analysis.
  • The cut-off applied is:

IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
compare the diagnostic accuracy assessed by ROC curve analysis between Perfusion Index (PI) & Internal Jugular Vein Collapsibility Index (IJVCI) combined with Cardiac Index (CI) in predicting post-spinal hypotension in elective CS patients.
Time Frame: • Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
• Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.

Secondary Outcome Measures

Outcome Measure
Time Frame
measure systolic arterial blood pressure changes after spinal anesthesia.
Time Frame: immediately after spinal anesthesia
immediately after spinal anesthesia
Total ephedrine dose or phenylephrine dose /milligram.
Time Frame: throughout the operation
throughout the operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 9/2026 ANET 53

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.